Abstract | Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours -particularly in the development of castration-resistant prostate cancer. WNT signalling is also important in the prostate tumour microenvironment, in which WNT proteins secreted by the tumour stroma promote resistance to therapy, and in prostate cancer stem or progenitor cells, in which WNT-β-catenin signals promote self-renewal or expansion. Preclinical studies have demonstrated the potential of inhibitors that target WNT receptor complexes at the cell membrane or that block the interaction of β-catenin with lymphoid enhancer-binding factor 1 and the androgen receptor, in preventing prostate cancer progression. Some WNT signalling inhibitors are in phase I trials, but they have yet to be tested in patients with prostate cancer.
Prostate cancer was the most commonly diagnosed cancer and second leading cause of cancer death in men in the USA in 2016 (REF. 1 ). Androgen deprivation therapy (ADT) is the standard of care for men with prostate cancer, owing to the essential role of the androgen receptor (AR) in the normal growth and development of the prostate gland, as well as in prostate carcinogenesis [2] [3] [4] . Unfortunately, most tumours progress to an aggressive state, known as castration-resistant prostate cancer (CRPC), despite ADT [5] [6] [7] . Several mechanisms, most of which are AR-dependent, are involved in the development of resistance. These mechanisms include the amplification and/or mutation of AR, expression of AR splice variants, increased production of androgens, and changes in the activity or expression of AR co-activators and co-repressors [7] [8] [9] . However, other, often AR-independent, signals have been implicated in the acquisition of resistance, among them are those triggered by WNT family proteins 10 . This Review focuses on new findings since our last review of the topic in 2012 (REF. 11 ). These data demonstrate that the field of WNT signalling research has progressed both at the level of basic research, in which noncanonical WNT signalling is now recognized as an important contributor to prostate cancer progression and new regulators of canonical WNT signalling at the cell membrane have been identified, and at the clinical level, as WNT signalling inhibitors are now in early-stage clinical trials (TABLE 1 ).
An overview of WNT signalling
The WNT family comprises 19 cysteine-rich, secreted lipoglycoproteins that have fundamental roles during embryonic and organ development by regulating stem cell self-renewal and cell proliferation, migration, and differentiation [35] [36] [37] . WNTs bind to transmembrane frizzled (FZD) receptors and a variety of co-receptors, including low-density lipoprotein receptor (LRP)4, LRP5, and LRP6, inactive tyrosine-protein kinase transmembrane receptor ROR (ROR)1 and ROR2, and tyrosine-protein kinase RYK (RYK) 38 to activate canonical (β-catenin-dependent) and noncanonical (β-catenin-independent) signals (FIG. 1) .
A hallmark of canonical WNT signalling is the stabilization and nuclear translocation of the protein β-catenin. In the absence of WNT ligands, β-catenin is recruited and degraded by the destruction complex, whose components include axin, glycogen synthase kinase-3 (GSK3), casein kinase 1 (CK1), and adenomatous polyposis coli protein (APC). WNT binding to FZD receptors and LRP5 and LRP6 co-receptors results in the phosphorylation of the latter by CK1 and GSK3, and recruitment of axin and dishevelled (DVL) to the plasma membrane, thereby disrupting the destruction complex. This disruption results in the stabilization of β-catenin, which accumulates in the cytoplasm and enters the nucleus, binding to T-cell factor-lymphoid enhancer-binding factor 1 (TCF-LEF) family transcription factors and co-activators, such as the CREBbinding protein (CBP)-histone acetyltransferase p300 (p300 HAT) family and B-cell lymphoma 9 protein (BCL9) and BCL9-like protein (BCL9L), and regulating the expression of WNT target genes 39 (FIG. 1) .
A novel branch of WNT signalling, WNT-dependent stabilization of proteins (WNT-STOP) 40 , was described in 2014. In this signalling cascade, the signal is initiated by WNT binding to LRP6 but the effects are transcriptionindependent, involving cyclin-Y, rather than β-catenin 40 .
WNT-STOP signals promote protein stabilization at mitosis. The targets are involved in cell-cycle progression, endolysosomal biogenesis, DNA remodelling and the cytoskeleton, so WNT-STOP signals could be important in cancer initiation and progression 41 (FIG. 1) .
Noncanonical WNT signals are less well defined than canonical signals. Noncanonical signals are traditionally subdivided into planar cell polarity (PCP) and WNT-Ca 2+ pathways 39 , although additional β-catenin-independent and TCF-independent signals also exist 42 . Noncanonical WNT signals are activated upon WNT binding to FZD receptors and tyrosinekinase-like co-receptors, resulting in the recruitment and activation of DVL. The PCP pathway has two parallel branches involving small GTPases: Rho, which activates Rho-associated kinase (ROCK), and Rac, which is linked to c-Jun-N-terminal kinase (JNK), and signalling by activator protein 1 (AP1) family transcription factors. Cytoskeletal and tran scriptional changes associated with these small GTPases regulate cell adhesion and migration 39, [42] [43] [44] . Activation of the WNT-Ca 2+ pathway stimulates Ca 2+ release from the endoplasmic reticulum, promoting activation of G-proteins, protein kinase C (PKC), and Ca 2+ /calmodulin-dependent kinase type II (CaMKII). These events can also result in the activation of transcription factors, such as nuclear factor of activated T-cells (NFAT), which promotes cell growth, survival, invasion, and angiogenesis 42, 43, 45, 46 (FIG. 1) .
In 2010, novel associations were identified between WNT and Hippo signalling, which regulates organ size, tissue homeostasis, and patterning 47 . Hippo signals are transduced by yes-associated protein (YAP), tran scriptional co-activator with PDZ-binding motif (TAZ), and TEA domain family transcription factors (TEADs) 48 . YAP-TAZ signals antagonize canon ical WNT signalling by binding to components of the destruction complex, such as axin 49 , and regulating nuclear translocation of β-catenin (FIG. 1) . In addition, a noncanonical WNT-YAP-TAZ signalling axis has been described, in which WNT binding to FZD and ROR activates Gα 12, Gα 13 , Rho, and large tumour suppressor homologue (LATS)1 and LATS2 to induce YAP-TAZ signals and TEAD-dependent transcription 50 . The importance of this alternative WNT signalling pathway in prostate cancer is yet to be examined.
The specific mechanisms by which WNT proteins stimulate these different responses are not fully elucidated, but are anticipated to involve the binding and activation of distinct WNT receptors 51, 52 . FZD family receptors have a role in most WNT signalling pathways. These seven-pass transmembrane proteins have an extracellular, cysteine-rich domain (CRD) that is essential and sufficient for WNT binding [53] [54] [55] . The crystal structure of the mouse Fzd8 CRD bound to Xenopus wnt8 shows the ligand resembling a hand with the thumb and index finger grasping the receptor. The thumb's palmitoleic acid group projects into a deep groove in the CRD (Site 1), whereas the finger interacts with a small depression in the CRD (Site 2) 56 (FIG. 2) . The lipid thumb domain of wnt8 interacts with residues conserved among FZD family members, accounting for the promiscuity of WNT-FZD interactions; however, some Site 2 residues are not conserved. For example, Met149 is present in five of ten mammalian FZD proteins 56 , suggesting that Site 2 interactions are responsible for binding specificity 56 . This structure also suggested a potential binding site for WNT co-receptors: a conserved solvent-exposed patch of 10 residues on the opposite side of wnt8 to the FZD binding site 56, 38 (FIG. 2) . Additional insight into WNT-FZD interactions comes from two independent structural studies of FZD CRDs in complex with fatty acids, which show that the acyl group promotes FZD CRD dimerization and support a 1:2 stoichi ometry model for WNT-FZD complexes 57, 58 . Moreover, palmit oy lated WNT-5A and WNT-8A stabilize the FZD4-CRD-CRD interaction, suggesting that FZD receptors form signalosomes (multiprotein complexes containing membrane-localized WNT receptors and cytosolic protein complexes containing AXIN and DVL capable of transmitting the WNT signal) upon WNT binding and that the WNT palmitoleoyl group is crucial for this interaction 57 . Additional studies will be required to determine how these interactions orchestrate WNT signalosome assembly.
Apart from FZD receptors, the single-pass transmembrane WNT receptors LRP5 and LRP6 are best known for transducing β-catenin-dependent signals. These receptors form a trimeric complex with WNT and FZD that is essential for activation of the canonical pathway 38, 55 . By contrast, ROR1 and ROR2 have CRDs related to the FZD CRD and activate non canonical signals 38, 42, 59 . In addition, RYK binds WNT proteins via a WNT inhibitory factor (WIF) domain and is implicated in canonical and noncanonical signalling 38, 59 . Protein-tyrosine kinase 7 (PTK7), also known as colon carcinoma kinase 4 (CCK4), which is involved in the PCP pathway and has a less well-defined WNT binding site than RYK, ROR1, and ROR2 (REF. 60 ). ROR1, ROR2, RYK, and PTK7 have intracellular tyrosine-kinase-like domains but they are most likely pseudokinases because these domains lack key residues found at the catalytic site of active kinases and they are devoid of detectable kinase activity in in vitro assays. Conditions for their cata lytic activation might not have been found yet, but the likeli hood is that they function in association with FZDs, other WNT receptors, and via allosteric activation of intracellular and 59, 61, 62 . By contrast, the ROR-related kinase, muscle, skeletal receptor tyrosineprotein kinase (MuSK), which also binds WNTs via a CRD, is catalytically active 38 , as is tyrosine-protein kinase receptor CAM-1, the Caenorhabditis elegans ROR homologue, suggesting that the signalling mechanisms of this family of kinases have diverged.
Regulation of WNT signalling by secreted WNT antagonists is more complex than that of the receptors. These antagonists can be divided into two classes: those that bind WNT proteins, such as secreted frizzled-related proteins (sFRPs), WIF1 and Cerberus, and those that associate with the WNT co-receptors LRP5 and LRP6, namely Dickkopf-related protein (DKK)1, DKK2, and DKK4 . DKK3 is a unique member of this family that does not bind LRP5 or LRP6, but can affect WNT signalling indirectly 65 . Adding further complexity, sFRPs can also bind to FZD receptors and activate or inhibit WNT signalling 63, 66 .
Results of studies published between 2013 and 2016 have revealed additional mechanisms of regulation of WNT signalling at the cell membrane 64, 65, 67 . The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 inhibit WNT signalling by targeting FZD receptors for ubiquitylation and degradation. ZNRF3 and RNF43, in turn, are regulated by R-spondins (RSPO1-RSPO4), which are secreted proteins that enhance WNT signalling by simultaneously binding ZNRF3 and RNF43 and leucine-rich repeat-containing G protein-coupled receptors (LGR4-LGR6) to promote ubiquitylation and membrane clearance of ZNRF3 and RNF43, facilitating FZD receptor stabilization 67, 68 (FIG. 3) .
WNT signalling pathway alterations Dysregulation of the WNT signalling pathway has been observed in several types of cancer, and some major alterations have been found in prostate cancer in the past 5 years Canonical effectors. β-catenin is the key effector of the canonical WNT pathway. The stability of β-catenin is tightly regulated by a destruction complex of associated proteins, including axin and APC, which promotes its phosphorylation, ubiquitylation, and degradation; the presence of cytoplasmic and/or nuclear β-catenin provides an indication of dysregulation. By contrast, the pool of β-catenin at the plasma membrane is protected from degradation by its interaction with cadherins. A considerable proportion of prostate tumours have increased levels of β-catenin in the cytoplasm and/or nucleus either as a result of gene mutations, or, more frequently, nongenomic changes in the expression of inhibitors and activators of WNT signalling 11 . Activating mutations in the gene encoding β-catenin (CTNNB1) and inactivating mutations in the genes that encode proteins in the destruction complex (APC and AXIN1) increase WNT-β-catenin signalling in many types of cancer, particularly colorectal cancer, but are infrequent in prostate cancer 10, 11 . However, genetic and epigenetic changes have been discovered that activate WNT-β-catenin signalling and could, therefore, contribute to prostate cancer progression. Genetic changes that activate WNT-β-catenin signalling are more frequently observed in castration-resistant prostate cancer (CRPC) than in treatment-naive prostate cancer. Recurrent alterations in CTNNB1 were observed in 12% of CRPC samples 70 .
Comparison of CRPC and high-grade, untreated, localized prostate tumours uncovered alterations in APC in 22% of lethal, castration-resistant tumours and in none of the untreated tumours 71 , and a multi-institutional study of 150 metastatic CRPC tumours revealed genomic alterations affecting APC and CTNNB1 in 18% of samples 72 . In addition, analysis of single nucleotide poly morphisms (SNPs) in WNT pathway genes identified links between gene variants of APC and reduced PSA-free survival 73 and prostate cancer progression 74 . A variety of cell systems and mouse models have been used to determine the outcome of β-catenin stabilization in nonmalignant prostate cells and prostate cancer cells 10, 11 . Studies in mice show that genetic activation of WNT-β-catenin signalling by a stabilized form of β-catenin or by Apc deletion results in high-grade prostate intraepithelial neoplasia (PIN). However, progression to invasive carcinoma requires a second event, for example, overexpression of serine protease hepsin 75 or deletion of phosphatase and tensin homologue (PTEN) 76 . Association of β-catenin with binding partners in the nucleus, such as TCF-LEF family transcription factors, protects β-catenin from the destruction complex by competing with APC and axin for binding to the β-caten in armadillo repeat domain, as is the case with cadherins at the plasma membrane. All four TCF-LEF family members are expressed to varying extents in the prostate and in prostate tumours, but LEF1 has been the focus of most studies, as it is upregulated in androgenindependent tumours 77 . LEF1 is a WNT-β-catenin target gene and also a target gene of transcriptional regulator ERG (ERG), which is upregulated in ~50% of prostate tumours 78 . A 2016 study comparing β-catenin and LEF1 levels in prostate tumour microarray (TMA) samples showed increases in the proportion of cells co-expressing β-catenin and LEF1 in localized prostate cancer and in tumour metastases, which suggests a role for β-catenin-LEF1-mediated transcription in both malignant transformation and metastasis of prostate cancer 79 . TCF-LEF family members are the key mediators of β-catenin-dependent transcription, but other transcription factors also interact with β-catenin in specific cell types and tissues. The AR is a crucial partner for β-catenin in prostate cancer. Given the influence of AR in prostate cancer, the importance and consequences of this interaction have been studied in detail 11, 80, 81 . Co-expression of AR and cytoplasmic β-catenin in patient tumour samples correlates with high primary Gleason grade (4-5), disease progression, and PSA levels in patients 82 , and AR and WNT signalling pathways are enriched in patients with early-onset prostate cancer (diagnosed at <50 years of age) 83 . In mice, the overexpression of human AR and stabilized β-catenin in prostate epithelial cells accelerates tumour development and invasion and reduces survival, suggesting that increased AR signalling enhances β-cateninmediated prostate tumour initiation 84 . Castration of these mice resulted in tumour regression, implying that AR signalling is also required for tumour maintenance 84 . If and how AR signalling and β-catenin-dependent signalling work together is not well understood. In this mouse study, both AR and β-catenin were recruited to regions of the myc proto-oncogene protein (c-Myc) locus containing Tcf-Lef family transcription factor binding sites 84 . In addition, gene expression microarray analysis showed that AR overexpression potentiated expression of some genes induced by stabilized β-catenin, including Myc, Spp1, and Egr1, which promote metastasis. However, it also reduced expression of the direct β-catenin gene targets Lef1 and Axin2 (REF. 84 ), consistent with previous studies in human cells showing competition between TCF-LEF family transcription factors and AR for binding to β-catenin 10, 11 . The interactions among AR, β-catenin, and TCF-LEF family transcription factors can be affected by the activation state of AR, with hormone deprivation or treatment with the antiandrogen enzalutamide redirecting β-catenin from AR to TCF4, leading to activation of WNT-β-catenin signalling 85 . These observations highlight the pathophysiological relevance and the complexity of the link between AR and WNT-β-catenin signalling in prostate cancer and suggest that a combination of antiandrogens and WNT inhibitors could improve the effectiveness of current treatments targeting the AR 85 . Other nuclear proteins might also activate WNT-β-catenin signalling in hormone-deprived cells, such as the nuclear form of the tyrosine-protein kinase MET, nMET 86 , and transcription factor SOX (SOX)4 (REFS 87,88).
WNT ligands and their receptors
The low frequency of WNT signalling pathway gene mutations in the majority of prostate tumours has encouraged the study of upstream components of the pathway. Novel molecular mechanisms have been discovered that stabilize WNT receptors at the membrane to sustain WNT signals. However, these receptors still require the presence of WNT ligands, the study of which has been hampered by their low expression and/or the lack of specific antibodies. For example, gene expression analysis indicates that WNT1 mRNA is low or undetectable in prostate cancer cell lines 78, 89, 90 , and lower in organ confined (pT2) and non-organ-confined (pT3/4) tumours than in benign prostatic hyperplasia, and highly expressed in advanced prostate cancer 90 . However, immunohistochemical analysis detected high expression of WNT-1 in prostate cancer cell lines, primary tumours, and metastases 91 . An emerging theme is the activation of non canonical WNT signalling in advanced prostate cancer and/or in CRPC. WNT-5A is upregulated in prostate cancer and can promote prostate tumour cell invasion through FZD2 and ROR2 (REF. 92 ). Moreover, Wnt-5a haploinsufficiency in a mouse model of prostate cancer prevents the early onset and early lethality of prostate tumours 93 . However, some reports contradict the protumorigenic effect of WNT-5A, correlating high WNT-5A expression with improved outcomes in localized, low-grade prostate cancer [94] [95] [96] . In other cancers, such as liver, breast, and lung, the WNT-5A-FZD2 complex has been reported to associate with the protein tyrosine kinase FYN and signal transducer and activator of transcription 3 (STAT3) to promote the epithelial-mesenchymal transition (EMT) and cell migration 97 . One possible explanation for the discrepancy is that the tumour-suppressing role of WNT-5A results from inhibition of canonical signalling and its tumour-promoting role from activation of non canonical signalling, consistent with association of increased expression of WNT5A and FZD2 with metastasis and biochemical recurrence 98 . Evidence exists that supports a role for WNT-5A in the development of resistance to ADT: WNT5A mRNA is detectable in circulating tumour cells (CTCs) from patients with CRPC 99 and from patients with prostate cancer whose disease progressed while they were undergoing treatment with the AR inhibitor enzalutamide 100 . WNT-7B, which had been previously observed to be upregulated in prostate cancer 101 , was shown to be an AR target gene in CRPC 100 . WNT-7B activates a noncanonical signal involving PKC and can induce an osteoblastic response in bone 102 . WNT-11 is also upregulated in prostate cancer, but, in contrast to WNT-7B, its expression is repressed by androgens 103 . WNT11 mRNA expression is elevated in tumours from patients receiving ADT 104 and cell studies show that this WNT is required for prostate cancer cell invasion and neuroendocrine-like differentiation 105 . Many WNTs are observed to be upregulated in certain settings: mRNA expression of WNT5B, WNT6, WNT10A, and WNT16 is increased in tumours from patients after ADT 106 , and WNT2, WNT3A, and WNT11 mRNAs are induced by ERG 78 , an oncogene expressed in prostate cancer exhibiting TMPRSS2-ERG gene fusion 107, 108 . 90 . In addition, SOX9, a critical effector of ERG, is required for increased expression of FZD7 (REF. 112 ), which is also upregulated in patients after ADT 106 . Evidence for increased expression of WNT co-receptors in prostate cancer is not as prevalent as the evidence for that of the FZD family. However, ROR1 protein was shown to be expressed in 19 of 21 prostate tumours, as well as in many other types of cancer, such as lung, ovarian and colorectal, in which it is linked to increased AKT and CREB phosphorylation and increased cell proliferation 113 . Together, these studies identify a limited number of WNTs and WNT receptors as potential therapeutic targets, particularly in the setting of CRPC.
WNT signalling regulators
A common theme in prostate cancer is the loss of expression of genes that encode secreted factors that inhibit WNT signalling, usually through promoter methylation. These include genes that encode WNT binding proteins, such as WIF1 (for which restoration of expression reduces tumour cell motility and reverses EMT 114 ) and sFRP1 (REFS 10,11) (expression of which inversely correlates with β-catenin expression and is a favourable predictive and prognostic biomarker in prostate cancer 115 ). One study showed reduced mRNA expression of SFRP1 and SFRP5 in prostate cancer but an increase in SFRP4 (REF. 116 ). SFRP2 expression is also downregulated in prostate cancer by promoter methylation 117, 118 . sFRPs do not always inhibit WNT signalling; for example, sFRP2 potentiates WNT-16B signalling to promote PC3 prostate cancer cell resistance to mitoxantrone, a genotoxic agent frequently administered to patients with prostate cancer as a second-line therapy 119 . Dickkopf proteins can be protumorigenic in some settings, despite their function as WNT inhibitors and the observation that they are frequently silenced in cancer by gene promoter methylation. In prostate cancer, high levels of DKK1 in serum are associated with poor patient prognosis 120 . Furthermore, overexpression of DKK1 promotes prostate tumour growth and the incidence of bone metastases 121 , and induces osteolytic lesions 122 . Some of the effects of DKK1 have been interpreted in the context of its ability to inhibit canonical signalling, resulting in activation of noncanonical signalling. However, the discovery in 2016 of an unrelated receptor for DKK1, cytoskeleton-associated protein 4 (CKAP4), indicates that DKK1 can also enhance cell proliferation independently of its effects on WNT signalling 123 . Among the other proteins that regulate WNT signalling at the cell surface, mutations in the ubi quitin ligases RNF43 and ZNRF3 and gene fusions that increase expression of RSPO2 were detected at an overall frequency of 6% in a panel of 150 metastatic CRPC tumours 72 , suggesting novel therapeutic options might be a possibility for some patients with prostate cancer.
WNT and the tumour microenvironment
The development and progression of cancer involves several signals that rely on the intrinsic properties of the tumour cells. However the interaction of cancer cells with other cell types in the tumour microenvironment, both in the primary tumour and at sites of metastasis, is also important 124 . Prostate stromal cells secrete several WNT family members that can influence tumorigenesis and disease progression (FIG. 4) . This secretion is exemplified by studies in mice showing that stromal Wnt-3a activates canonical Wnt signalling in the epithelium, facilitating progression of PIN lesions to adenocarcinoma and resistance to androgen deprivation 125 . Stromal overexpression of high mobility group protein Hmci-c in mice was observed to promote development of multifocal PIN lesions that were accompanied by increased expression of Wnt2, Wnt4, and Wnt9a, and could be suppressed by overexpression of sFRP1 and Dkk1 (REF. 126 ). WNT10B is among the genes upregulated in human prostate cancer stroma, and silencing it reduces the protumorigenic effects of stromal cells on LNCaP tumour growth in xenograft assays 127 . WNT signals from the tumour microenvironment are also involved in the development of resistance to therapy. Therapy-induced DNA damage increases the expression of WNT-16B in prostate fibroblasts 128 , which activates canonical WNT signalling in tumour cells and promotes therapy resistance and disease progression 128 . Further studies are required to determine the importance of stromalderived WNT-16B and of other WNT family members, such as WNT-5A 129 , at different stages of prostate cancer.
WNT signalling and cancer stem cells
In prostate and other cancers, such as breast, pancreas, colon, lung, and brain, the cancer stem (or progenitor) cell (CSC) population shares many characteristics with somatic stem cells, such as immortality and self-renewal, and is believed to be a source of tumour-initiating cells and also be responsible for tumour recurrence, metastasis, and chemoresistance 130, 131 . WNT-β-catenin signalling was shown to promote prostate CSC renewal and expansion in 2009 (REF. 132 ). In 2015, one study showed that shRNA-mediated silencing of the tumour suppressor gene DAB2IP in human prostate epithelial cells generated CSC with activated WNT-β-catenin signalling 133 . In this model, WNT-β-catenin signals directly induced expression of the stem cell marker gene CD44, and inhibitors of WNT secretion synergized with docetaxel to inhibit tumour growth in vivo 133 . In addition, the mRNA and protein expression of ALDH1A, another CSC marker that is also a direct target of WNT-β-catenin signalling, is elevated in radioresistant prostate cancer cells 134 . Inhibition of WNT-β-catenin signalling using the tankyrase inhibitor XAV939 or siRNA-mediated knockdown of β-catenin reduced ALDH1A mRNA and protein levels, reduced the population of ALDH-positive CSCs, and increased cancer cell sensitivity to irradiation 134 . These results provide a rationale for using inhibitors of WNT-β-catenin signalling to target prostate CSCs and thereby reduce the development of tumour resistance to therapy 135 .
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Targeting WNT signalling The variety of changes observed in WNT pathway components has the potential to provide therapeutic opportunities, particularly in advanced prostate cancer. Several drugs that target WNT signalling are in development (FIG. 5) , but very few of them are being tested for the treatment of prostate cancer 136 . This omission might reflect a general impression that WNT signalling has a minor role in prostate cancer, based on the low frequency of WNT pathway mutations in primary tumours. The increased frequency of APC mutations, identification of novel mutations in CRPC, and the increasing evidence that noncanonical WNT signals are active in prostate cancer, are expected to stimulate further interest in this area of drug development.
Several FDA-approved drugs in current use affect WNT-β-catenin signalling 137 , and at least one of these -aspirin -is associated with reduced prostate cancer risk 138 . Specific WNT pathway inhibitors can be classified into functional groups: inhibition of WNT secretion, regulation of antagonists and agonists, targeting WNT receptor interactions, preventing DVL activation, stabilizing the destruction complex, and targeting nuclear β-catenin partners.
Inhibition of WNT secretion. Porcupine, a membranebound O-acetyltransferase, is uniquely responsible for WNT palmitoylation of WNT proteins, which is essential for their secretion 139 . Targeting porcupine has been used extensively to inhibit WNT signalling in different cancer types. The first reported porcupine inhibitors, Inhibitors of WNT Production (IWPs, the best known of which is IWP-2), were identified in a synthetic chemical screen 140 . Several other porcupine inhibitors have since been reported. These inhibitors include WNT-C59, which inhibits growth of Wnt-1-expressing mammary tumours in mice 141 ;
LGK974 (REF. 142 ), an orally bioavailable inhibitor that reduces tumour growth in rodent models of breast cancer, head, and neck cancer 142 , and of xenografts of pancreatic tumours with RNF43 mutations 143 ; and ETC-159, another orally bioavailable molecule, which inhibits growth of patient-derived xenografts of colorectal cancers with RSPO fusions 144 .
LGK974 (now known as WNT974) entered a phase I trial in 2011 (still ongoing), for patients with tumours that have mutations in RNF43 and ZNRF3 or RSPO gene fusions 12 .
Preliminary clinical data suggested LGK974 has a manage able safety profile and potential for antitumour activity 145 . An ongoing phase I/II trial is using LGK974 in combination with the RAF inhibitor LGX818 and the EGFR inhibitor cetuximab in patients with BRAFV600-mutant, KRAS wild-type metastatic colorectal cancer harbouring RNF43 mutations or RSPO fusions 13 . ETC-159 (long name ETC-1922159) has also entered a phase I trial in patients with advanced solid tumours 14 and preliminary data indicate that this drug is safe and well tolerated, and dose escalation is on going 146 (TABLE 1) .
The identification of RNF43 and ZNRF3 mutations and RSPO2 gene fusions in CRPC 72 in 2015 provides hope that porcupine inhibitors might also be assessed in patients with advanced prostate cancer.
Regulation of antagonists and agonists. Many secreted WNT antagonists are epigenetically silenced in cancer, and drugs that target the epigenetic machinery can restore their expression. For example, treatment of renal cancer cells or breast cancer cells with combined therapy of the histone deacetylase (HDAC) inhibitor romidepsin and the DNA methyltransferase (DNMT) inhibitor decitabine reactivates SFRP1 expression to inhibit growth and induce apoptosis in an sFRP1-dependent manner 147 . Application of recombinant sFRP1 proteins could also be a therapeutic option 148 , as is the case for DKK3, which preclinical studies have shown is an effective treatment for prostate cancer and other cancers, including breast cancer, gastric carcinoma, and malignant mesothelioma 149 . A phase I/II clinical trial started in 2013 using an adenoviral vector expressing DKK3 in patients with localized prostate cancer 15 has reported promising results, showing reduced metastatic tumour growth in a case study of a patient with treatment-resistant disease and antitumour activity and reduced biochemical recurrence-free survival in patients with high-risk localized prostate cancer 150, 151 (TABLE 1) .
Another approach to targeting tumours that contain RSPO fusions is to use function-blocking antibodies; as has been done for RSPO3 in colorectal cancer Targeting WNT receptor interactions. WNT ligands and their receptors are attractive targets for therapy because they are accessible to monoclonal antibodies and small molecules 153 . WNT-5A has been targeted using antibodies and a WNT-5A-derived peptide called Foxy-5. The WNT-5A antibodies reduce metastasis of gastric tumour cells 154 but have not been tested for their effects on prostate cancer metastasis. These antibodies do not block WNT receptor binding, but they inhibit WNT-5A-induced internalization of FZD2 and ROR2 (REF. 155 ). Foxy-5 is a formylated hexapeptide that inhibits breast cancer metastasis 156, 157 . The first phase I trial failed to reach a maximum tolerated dose 17 , so a second trial is recruiting patients with metastatic breast, colon, or prostate cancer 18 (TABLE 1) . Given that the antibodies inhibit WNT-5A signalling and Foxy-5 activates it, and in light of the contrasting reports on the prognosis of high WNT-5A expression in prostate cancer, stratifying patients before using treatments that target WNT-5A will be important.
Antibodies are not the only tool for targeting WNT proteins: a recombinant fusion of the ligandbinding domain of FZD8 and the crystallizable fragment domain of a human IgG1 (OMP-54F28, also known as FZD8-Fc or ipafricept) is a decoy WNT receptor that inhibits the proliferation of CSCs and induces tumour differentation 158 . In a phase Ia clinical trial, this drug was well tolerated and demonstrated evidence of WNT pathway modulation and potential early single-agent activity manifested by prolonged stable disease 19, 159 . Now, trials of this therapy in combination with other drugs are being conducted in ovarian 20, 160 , liver 21 , and pancreatic cancer 22 (TABLE 1) .
The success of porcupine inhibitors in blocking all WNTs and the possibility of redundancy among members of the WNT family in cancer has led to increased efforts to target WNT receptors, rather than WNT proteins. FZD7 is one of most frequently upregulated WNT receptors in many cancers, including intestinal cancer, hepatocellular carcinoma, gastric cancer, and breast cancer, and it has been targeted using both decoy receptor and antibody approaches 161 . OMP-18R5 (vantictumab) targets FZD1, FZD2, FZD5, FZD7, and FZD8. In preclinical models, this therapy reduces CSC frequency and induces differentiation of tumori genic cells to cell types that are less tumorigenic and/or more susceptible to conventional chemotherapy. OMP-18R5 exhibits strong antitumour activity in combination with other approved therapies in patient-derived xenograft (PDX) models, including cancers of the pancreas, breast, lung, liver, ovary, and colon 162 . Phase Ib clinical trials of OMP-18R5 in combination with standard-of-care chemotherapy have been carried out in HER2-negative breast cancer and advanced pancreatic cancer [23] [24] [25] [26] (TABLE 1) . In 2017, OMP-18R5 and OMP-54F28 were shown to potentiate the effects of taxanes in PDX models. This phenomenon involved sensitization of cancer cells to taxanes and required treatment with the WNT inhibitor before mitotic blockade with paclitaxel 163 . This combination strategy has been incorporated into ongoing clinical trials of OMP-54F28 and OMP-18R5 with other chemotherapeutic agents 20, 22, 25, 26 . Other FZD antibodies are patented for the treatment of cancer, for example OTSA101, a radiolabelled antibody against FZD10 (REF. 164 ), in phase I trials for , drugs that target WNT receptor interactions (green), drugs that prevent dishevelled (DVL) activation (pink), drugs that stabilize the destruction complex (grey), and drugs that target β-catenin (β-cat) partners in the nucleus (purple). APC, adenomatous polyposis coli protein; CBP, CREB-binding protein; CK1, casein kinase 1; DKK, Dickkopf-related protein; FZD, frizzled; GSK, glycogen synthase kinase; LRG, leucine-rich repeat-containing G protein-coupled receptor; LRP, low-density lipoprotein receptor; sFRP, secreted frizzled-related protein; TCF, T-cell factor; TAZ, transcriptional co-activator with PDZ-binding motif; ROR, tyrosine protein kinase transmembrane receptor; WLS, wntless homologue; YAP, yes-associated protein.
synovial sarcoma was found to be feasible and safe, but the number of patients accrued was too small to continue the study 27, 165 (TABLE 1) . In 2016, phage display was used to generate antibodies that recognize FZD5 and FZD8 that inhibit the growth of RNF43-mutant pancreatic tumour cells in vivo 166 . Among the non-FZD family receptors being targeted for therapy, LRP6 and ROR1 might be relevant to prostate cancer. The antihelminthic drug niclosamide has been reported to induce apoptosis in prostate cancer by targeting LRP6 (REF. 167 ). However, this therapy was also shown to downregulate oncogenic variants of AR and overcome enzalutamide resistance in CRPC 168, 169 , so whether its effects relate to LRP6 or AR, or both, is unclear. Other agents that target LRP6 exist and can affect prostate cancer cells, including salinomycin, which induces LRP6 degradation 170 , and Mesd, which acts as a chaperone for LRP5 and LRP6 and inhibits prostate tumour xenograft growth 171 . ROR1 expression is increased in a number of cancers, including prostate cancer 113, 172 . Given the importance of ROR1 in chronic lymphocytic leukaemia, a variety of approaches have been used to target it, including antibodies, chimeric antigen receptor T cells, and antibody-drug con jugates 173 . Among the antibodies, UC-961 (cirmtuzumab) is recruiting patients for phase I clinical studies for chronic lymphocytic leukaemia [28] [29] [30] and breast cancer 31 (TABLE 1) .
Preventing DVL activation. The DVL PDZ domain binds to the carboxyl terminal region of FZD receptors and is essential for signal transduction. Among the three DVL family members, DVL2 is upregulated in prostate tumours and silencing it inhibits prostate cancer cell proliferation and migration 174 . A number of DVL inhibitors have been reported, one of which has been shown to inhibit proliferation of the prostate cancer cell line PC-3
Stabilizing the destruction complex. Tankyrases 1 and 2 are poly (ADP-ribose) transferases (PARPs) that target axin1 and axin2 for proteasomal degradation. Their inhibitors are widely used to promote β-catenin degradation, thereby inhibiting canonical WNT signalling 176 . Several structurally distinct tankyrase inhibitors are now being developed for possible clinical use. Structurebased optimization of one of these, XAV939, resulted in the development of a more selective and orally bioavailable inhibitor, NVP-TNKS656, which inhibited WNT signalling in mouse mammary tumour virus (MMTV)-WNT-1 tumour-bearing mice 177 . Evidence exists that chronic WNT stimulation, which increases expression of the β-catenin partners LEF1 and B-cell CLL/lymphoma 9-like protein (BCL9L), renders tumour cells resistant to tankyrase inhibition because they shield β-catenin from axin 178 . This shielding might occur in prostate tumours that express high levels of LEF1 (REF. 79 ). Finally, it should be noted that tankyrase inhibitors might have effects not directly related to WNT signalling, as tankyrases bind and regulate several other proteins, including PTEN and angiomotin (AMOT) family proteins 176, 179, 180 .
Targeting nucleαr β-catenin partners. Transcriptional activation by β-catenin requires interaction both with TCF-LEF family transcription factors and other coactivators, such as CBP or p300, which associate with the carboxyl terminal transactivation domain in β-catenin. Thus, the disruption of these interactions might provide new therapies. Small molecule inhibitors of β-cateninresponsive transcription have been identified that disrupt the β-catenin-TCF4 interaction, including the inhibitors of catenin responsive transcription (iCRTs) 181 , BC21, which was identified in virtual docking studies using a compound library and the crystal structures of β-catenin alone and in complexes with TCF3 and TCF4 (REF. 182 ), and LF3, a 4-thioureido-benzenesulfonamide derivative identified in a high-throughput screen of 16,000 compounds 183 . In 2004, ICG-001, a first-in-class modulator of WNT signalling, was observed to inhibit binding of β-caten in to CBP 184 , and a derivative, PRI-724, is in phase I clinical trials in different solid tumours 32 and has been reported to have an acceptable toxicity profile 185 . Results are anticipated from completed phase I trials in patients with pancreatic cancer 33 and leukaemia 34 (TABLE 1) . In addition, a compound named Windorphen has been identified that prevents p300 binding to β-catenin and reduces the viability of PC3 and DU145 cells in vitro 186 . Both CBP and p300 have many other partners, so these compounds also have WNT-independent effects that can lead to induction of caspase-3-dependent apoptosis and cell-cycle arrest 187 . Two further inhibitors that affect β-catenin-dependent transcription are triptonide, a small molecule identified from the traditional Chinese medicine Tripterygium wilfordii that targets the C-terminal domain of β-catenin 188 , and an orally bioavailable WNT inhibitor that acts at or downstream of TCF, identified in a cell-based screen 189 . The former has been shown to promote apoptosis of cancer cells, including PC3 and DU145 prostate cancer cells 188 and the latter inhibited tumour growth in colon cancer xenografts 189 . Given the number of studies on the interaction between β-catenin with AR, the fact that no drug screens targeting this complex have been performed is surprising. However, a group of investigators used the overlap of the interaction domains of AR and TCF-4 on β-catenin and observed that iCRT3 (REF. 181 ) inhibited both AR and WNT-β-catenin signalling and reduced prostate tumour growth in vivo 190 . The effect of iCRT3 on AR binding to target genes was accompanied by a reduction in binding of co-activator-associated arginine methyltransferase 1 (CARM1, also known as PRMT4), a cofactor for AR and β-catenin and another therapeutic target 190 .
Conclusions
WNT signalling has fundamental roles in prostate carcinogenesis. Both autocrine signalling in tumour cells and paracrine signalling from the tumour microenvironment are involved in prostate tumorigenesis, meta stasis, and therapy resistance. Given the possibility that drugs that specifically target WNT signalling components will reach the clinic, the question that arises is whether canonical or noncanonical WNT signals are more critical in prostate cancer. The answer might be tumour-stage and context dependent. Canonical WNT signals could be more important to support prostate cancer stem (or progenitor) cell proliferation and/or survival, than noncanonical signals, particularly under conditions of androgen deprivation, whereas non canonical WNT signals, by endowing tumour cells with migratory and/or invasive properties, might be more important at early stages of tumour spread. Both could be critical in metastatic CRPC, in which both activating mutations in canonical WNT signalling and activated noncanonical WNT signalling have been observed. Several agents that target WNT signalling at different levels of the pathway have been developed, and some of these have reached clinical trials (TABLE 1) .
However, not many of them have been tested as possible therapies for prostate cancer. Mutations in CTNNB1 and APC are relatively infrequent in primary tumours, but they are more prevalent than originally thought in advanced tumours and CRPC, and are accom panied by increased noncanonical WNT signalling. In addition, novel WNT pathway mutations have been discovered in CRPC. Together, these new discoveries provide hope for a subset of patients who might benefit from drugs currently in clinical trials that inhibit WNT signalling, particularly those affecting WNT secretion and/or WNT receptor binding, as well as those preventing β-catenin interaction with key transcription factors, such as LEF1 and AR.
